NDANASALSPRAY2 Generics Approved
Approved
May 2019
Lifecycle
LOE Approaching
Competitive Pressure
45/100
Clinical Trials
20
Data completeness
5/8 — Partial
NAYZILAM (midazolam) by UCB Pharma. Approved for benzodiazepine [epc]. First approved in 2019.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NAYZILAM (midazolam) is a short-acting benzodiazepine CNS depressant administered as a nasal spray, approved by the FDA in May 2019. It is indicated for sedation and anxiolysis, with rapid onset of action (sedative effects within 3-5 minutes intravenously, 15 minutes intramuscularly) and potent amnestic properties (71-91% of patients exhibit impaired recall depending on route and indication). The product demonstrates utility across multiple clinical settings including endoscopy, pediatric procedures, and anesthetic induction. NAYZILAM's nasal spray formulation represents a differentiated delivery mechanism within the benzodiazepine class, offering an alternative to traditional IV/IM administration.
$0.0BPart D
1.7 years to LOEMechanism of Action
Pharmacologic Class:
Benzodiazepine
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies
Started May 2026
24 enrolled
Advanced Malignancies
A Clinical Trial in Healthy Participants to Learn How Itraconazole Affects MK-2828 Levels and How MK-2828 Affects Midazolam Levels (MK-2828-007)
Started Mar 2026
28 enrolled
Healthy
A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.
Started Jan 2026
Drug-drug Interaction Study of Vorasidenib With Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, and Rosuvastatin in Healthy Adult Participants
Started Oct 2025
28 enrolled
Healthy Adult Participants
Pharmacokinetic Interaction Trial of Clofutriben With Midazolam and Prednisolone
Started Oct 2025
16 enrolled
Healthy Participants
Worked on NAYZILAM at UCB Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.